^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Non small cell lung cancer: Adenocarcinoma, Large Cell, NSCLC NOS...Preferred...Cemiplimab-rwlc + paclitaxel + (carboplatin or cisplatin)...
Secondary therapy:
carboplatin + paclitaxel; cisplatin + paclitaxel
